- Home
- SKYE vs MGTX Comparison
SKYE vs MGTX Comparison
Compare SKYE & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYE | MGTX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 744.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | MGTX |
|---|---|---|
| Price | $0.94 | $8.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $14.75 | ★ $23.83 |
| AVG Volume (30 Days) | 263.7K | ★ 632.2K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,417,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $619.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 96.83 |
| 52 Week Low | $0.99 | $4.55 |
| 52 Week High | $5.75 | $9.73 |
Technical Indicators
Market Signals| Indicator | SKYE | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 44.34 |
| Support Level | $1.04 | $8.25 |
| Resistance Level | $1.27 | $9.50 |
| Average True Range (ATR) | 0.10 | 0.56 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 1.48 | 21.32 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.